Trial Profile
Randomized phase II trial comparing temozolomide plus cisplatin, high-dose interferon alpha-2b or observation in resectable mucosal melanoma patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2012
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Interferon alpha-2b (Primary) ; Temozolomide (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
- 21 May 2012 Actual end date (Jul 2009) added as reported by Chinese Clinical Trial Register.
- 20 Dec 2011 New trial record